Phase IIb Trial of IRAK4 Inhibitor, PF-06650833, in Patients With Moderately to Severely Active RA and Inadequate Response to MTX

November 8-13, 2019; Atlanta, Georgia
PF-06650833 associated with improvements in SDAI in primary analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 171 KB
Released: November 18, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Mallinckrodt Pharmaceuticals

Related Content

Expert commentary on real-world and trial data on treating RA after failing biologic and targeted small-molecule DMARDs, from EULAR 2020 by CCO

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 27, 2020 Expired: August 26, 2021

Expert commentary on key studies in RA comorbidities from EULAR 2020 as reported by CCO

Paul Emery, MA, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 24, 2020 Expired: August 23, 2021

EULAR 2020 on SELECT-CHOICE: upadacitinib vs abatacept for active rheumatoid arthritis with prior inadequate response or intolerance to bDMARDs as reported by CCO

Released: August 17, 2020

New from EULAR 2020: risk of venous thromboembolism (DVT or PE) varies by DAS28 in patients with rheumatoid arthritis as reported by Clinical Care Options (CCO)

Released: August 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?